Opsoclonus-myoclonus syndrome in patients with locked-in syndrome: a therapeutic porthole with gabapentin
- PMID: 20511483
- PMCID: PMC2878256
- DOI: 10.4065/mcp.2010.0042
Opsoclonus-myoclonus syndrome in patients with locked-in syndrome: a therapeutic porthole with gabapentin
Abstract
Patients with locked-in syndrome, although fully conscious, have quadriplegia, mutism, and lower cranial nerve paralysis. The preservation of vertical gaze and upper eyelid movements usually enables them to interact with the environment through an eye-coded communication. However, locked-in syndrome may be complicated by the development of an opsoclonus-myoclonus syndrome that may represent an additional impediment to communication. We evaluated whether off-label treatment with gabapentin could help patients with locked-in syndrome and opsoclonus-myoclonus symptoms regain voluntary control of full eye movements. A mechanism responsible for gabapentin-induced improvement has been also hypothesized. In this study, 4 patients presenting with locked-in syndrome complicated by opsoclonus-myoclonus syndrome were continuously treated with gabapentin up to 1200 mg/d. The treatment resulted in a rapid and long-lasting resolution of opsoclonus-myoclonus symptoms without adverse effects. After 2 weeks, patients showed voluntary attempts to communicate through eye blinking and thereafter regained voluntary control of full eye movements. This event enabled them to regain a communication channel with relatives and physicians and to start using eye-controlled brain-computer interfaces. Because of its effectiveness in restoring eye movement control, gabapentin opened a communicative porthole in the patients' lives. Since opsoclonus may be related to disorders of the inhibitory control of saccadic burst neurons by pontine pause cells, we hypothesize that gabapentin acts as a regulator of saccadic circuits.
Figures



Comment in
-
New uses for older drugs: the tales of aspirin, thalidomide, and gabapentin.Mayo Clin Proc. 2010 Jun;85(6):508-11. doi: 10.4065/mcp.2010.0267. Mayo Clin Proc. 2010. PMID: 20511480 Free PMC article. No abstract available.
References
-
- Dumas A.The Count of Monte Cristo London, England: Wordworth Editions Limited; 1997.
-
- Bauer G, Gerstenbrand F, Rumpl E. Varieties of the locked-in syndrome. J Neurol. 1979;221(2):77-91 - PubMed
-
- Pistoia F, Sarà M. Gabapentin therapy for ocular opsoclonus-myoclonus restores eye movement communication in a patient with a locked-in syndrome. Neurorehabil Neural Repair. [published online ahead of print November 20, 2009] - PubMed
-
- Ware JE, Snow KK, Kosinski M, Gandek B. SF-36® Health Survey Manual and Interpretation Guide Boston, MA: New England Medical Center, The Health Institute: 1993.
-
- Hersh B, Dalmau J, Dangond F, Gultekin S, Geller E, Wen PY. Paraneo-plastic opsoclonus-myoclonus associated with anti-Hu antibody. Neurology 1994;44(9):1754-1755 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources